SSY Group Gains China Approval for New Drugs

  Published 1 year ago

SSY Group Ltd. received Chinese regulatory approval for two new pharmaceutical products: Dronedarone Hydrochloride Tablets (antiarrhythmic) and Gabexate Mesylate for Injection (pancreatitis treatment). This marks a significant advancement for the company.

  • Approval for antiarrhythmic drug, Dronedarone.
  • Gabexate Mesylate approved for pancreatitis.
  • Positive step for SSY Group's development.

You might like these

Tolins Tyres Surges 9.3% on Production Growth

Mangalam Cement Stock Rises on Mining Bid News

GRSE Wins Defence Contract, Shares Rise

Suryoday Bank Q1 FY26 Financial Highlights

Adani Green Shares Rise on Promoter Investment

India Seeks Gold Loan Rule Relaxations

Reliance Power Wins Major Solar + BESS Project

News that matters the most ⚡